DE3650751D1 - Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung - Google Patents

Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung

Info

Publication number
DE3650751D1
DE3650751D1 DE3650751T DE3650751T DE3650751D1 DE 3650751 D1 DE3650751 D1 DE 3650751D1 DE 3650751 T DE3650751 T DE 3650751T DE 3650751 T DE3650751 T DE 3650751T DE 3650751 D1 DE3650751 D1 DE 3650751D1
Authority
DE
Germany
Prior art keywords
antigens
production
peptides
antibodies against
mammalian interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3650751T
Other languages
English (en)
Other versions
DE3650751T2 (de
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE3650751D1 publication Critical patent/DE3650751D1/de
Application granted granted Critical
Publication of DE3650751T2 publication Critical patent/DE3650751T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Auxiliary Devices For Music (AREA)
  • Fertilizers (AREA)
DE3650751T 1985-11-19 1986-11-19 Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung Expired - Lifetime DE3650751T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79966985A 1985-11-19 1985-11-19
US79966885A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4

Publications (2)

Publication Number Publication Date
DE3650751D1 true DE3650751D1 (de) 2001-02-22
DE3650751T2 DE3650751T2 (de) 2001-08-02

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3650538T Expired - Lifetime DE3650538T2 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)
DE3650751T Expired - Lifetime DE3650751T2 (de) 1985-11-19 1986-11-19 Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3650538T Expired - Lifetime DE3650538T2 (de) 1985-11-19 1986-11-19 Interleukin-4 protein mit bcgf- und tcgf-aktivität gegenüber menschlichen zellen (menschliches interleukin-4)

Country Status (23)

Country Link
EP (3) EP0230107A1 (de)
JP (2) JP2557361B2 (de)
KR (1) KR940007773B1 (de)
CN (1) CN1020472C (de)
AT (2) ATE140009T1 (de)
AU (1) AU610057B2 (de)
CZ (1) CZ414191A3 (de)
DE (2) DE3650538T2 (de)
DK (1) DK371087A (de)
ES (2) ES2153444T3 (de)
FI (1) FI102075B1 (de)
GR (1) GR3021198T3 (de)
HK (2) HK1005594A1 (de)
HU (1) HU208710B (de)
IE (1) IE80828B1 (de)
IL (1) IL80678A (de)
MY (1) MY101972A (de)
NO (1) NO301234B1 (de)
NZ (1) NZ218332A (de)
OA (1) OA08947A (de)
PT (1) PT83761B (de)
SK (1) SK414191A3 (de)
WO (1) WO1987002990A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
WO1989001046A1 (en) * 1987-07-29 1989-02-09 Schering Biotech Corporation Purification of human interleukin-4 expressed in escherichia coli
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
DE3882611T2 (de) * 1987-08-03 1993-12-23 Tasuku Honjo Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
ES2058490T3 (es) * 1988-02-02 1994-11-01 Schering Biotech Corp Metodo de reducir respuestas de inmunoglobulina e.
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
WO1989010939A1 (en) * 1988-05-13 1989-11-16 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1990006765A1 (en) * 1988-12-21 1990-06-28 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
IL96714A0 (en) 1989-12-20 1991-09-16 Schering Corp Antibody antagonists of human interleukin-4
CA2078676A1 (en) * 1990-03-21 1991-09-22 Jerome Schwartz Use of il-4 to enhance immune response to infectious antigenic challenges
EP0563254B1 (de) * 1990-12-19 1995-11-08 Schering Corporation Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen
ATE135233T1 (de) * 1991-01-10 1996-03-15 Schering Corp Verwendung von il-4 zur verstärkung von wundheilung und besserung und zur heilung von infizierten wunden und wunden bei diabetischen säugetieren
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2331726C (en) * 1998-05-12 2010-03-09 Isis Pharmaceuticals Inc. Modulation of molecular interaction sites on rna and other biomolecules
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
LT2665486T (lt) 2011-01-18 2020-04-10 Bioniz, Llc Kompozicijos, skirtos gama-c-citokino aktyvumui moduliuoti
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
US11400134B2 (en) 2015-10-09 2022-08-02 Bioniz, Llc Modulating gamma-c-cytokine activity
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
WO1987004723A1 (en) * 1986-02-11 1987-08-13 Board Of Regents, The University Of Texas System Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
CZ414191A3 (en) 1993-04-14
ES2153444T3 (es) 2001-03-01
IE80828B1 (en) 1999-03-10
FI873141A0 (fi) 1987-07-16
CN86108579A (zh) 1988-01-27
EP0230107A1 (de) 1987-07-29
DE3650751T2 (de) 2001-08-02
EP0675136B1 (de) 2001-01-17
EP0249613A1 (de) 1987-12-23
SK414191A3 (en) 1995-07-11
ATE140009T1 (de) 1996-07-15
WO1987002990A1 (en) 1987-05-21
OA08947A (en) 1990-11-30
HK1008823A1 (en) 1999-05-21
JP2557361B2 (ja) 1996-11-27
KR940007773B1 (ko) 1994-08-25
CN1020472C (zh) 1993-05-05
JPH0884591A (ja) 1996-04-02
NZ218332A (en) 1993-04-28
IE863042L (en) 1987-05-19
DK371087A (da) 1987-09-21
ES2088858T3 (es) 1996-10-01
JPS63501401A (ja) 1988-06-02
PT83761B (pt) 1989-06-30
IL80678A (en) 1999-05-09
AU610057B2 (en) 1991-05-16
NO301234B1 (no) 1997-09-29
HUT43630A (en) 1987-11-30
NO872988L (no) 1987-09-18
JP2568394B2 (ja) 1997-01-08
EP0675136A3 (de) 1996-03-13
NO872988D0 (no) 1987-07-17
DK371087D0 (da) 1987-07-16
IL80678A0 (en) 1987-02-27
DE3650538D1 (de) 1996-08-08
FI873141A (fi) 1987-07-16
AU6733487A (en) 1987-06-02
GR3021198T3 (en) 1996-12-31
FI102075B (fi) 1998-10-15
DE3650538T2 (de) 1996-12-12
EP0249613B1 (de) 1996-07-03
PT83761A (en) 1986-12-01
EP0675136A2 (de) 1995-10-04
HK1005594A1 (en) 1999-01-15
MY101972A (en) 1992-02-29
FI102075B1 (fi) 1998-10-15
HU208710B (en) 1993-12-28
ATE198754T1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
DE3786592D1 (de) Transformation von trichoderma.
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
NO882946D0 (no) Konstruksjon av syntetisk dna og anvendelse derav i syntese av store polypeptider.
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ES2085329T3 (es) Agente anticanceroso proteico.
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition